Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) - Total Assets
Based on the latest financial reports, Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940) holds total assets worth CN¥2.92 Billion CNY (≈ $427.51 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Zhejiang Anglikang Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Total Assets Trend (2014–2024)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total assets have evolved over time, based on quarterly financial data.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's total assets of CN¥2.92 Billion consist of 50.4% current assets and 49.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.4% |
| Accounts Receivable | CN¥236.43 Million | 8.0% |
| Inventory | CN¥503.79 Million | 16.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥178.73 Million | 6.0% |
| Goodwill | CN¥312.94 Million | 10.5% |
Asset Composition Trend (2014–2024)
This chart illustrates how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002940 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Anglikang Pharmaceutical Co Ltd Class A's current assets represent 50.4% of total assets in 2024, a decrease from 54.9% in 2014.
- Cash Position: Cash and equivalents constituted 23.4% of total assets in 2024, up from 5.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 6.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 16.9% of total assets.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Competitors by Total Assets
Key competitors of Zhejiang Anglikang Pharmaceutical Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.72 | 2.56 |
| Quick Ratio | 1.29 | 1.20 | 2.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥693.40 Million | CN¥670.18 Million | CN¥848.21 Million |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Zhejiang Anglikang Pharmaceutical Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.25 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | CN¥2.97 Billion |
| Market Capitalization | $976.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Anglikang Pharmaceutical Co Ltd Class A's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhejiang Anglikang Pharmaceutical Co Ltd Class A's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2014–2024)
The table below shows the annual total assets of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.97 Billion ≈ $435.27 Million |
-1.51% |
| 2023-12-31 | CN¥3.02 Billion ≈ $441.92 Million |
+16.33% |
| 2022-12-31 | CN¥2.60 Billion ≈ $379.89 Million |
+24.60% |
| 2021-12-31 | CN¥2.08 Billion ≈ $304.89 Million |
+7.36% |
| 2020-12-31 | CN¥1.94 Billion ≈ $283.99 Million |
+40.13% |
| 2019-12-31 | CN¥1.38 Billion ≈ $202.67 Million |
-5.80% |
| 2018-12-31 | CN¥1.47 Billion ≈ $215.14 Million |
+62.13% |
| 2017-12-31 | CN¥906.78 Million ≈ $132.69 Million |
+24.56% |
| 2016-12-31 | CN¥727.99 Million ≈ $106.53 Million |
-8.98% |
| 2015-12-31 | CN¥799.83 Million ≈ $117.04 Million |
+9.35% |
| 2014-12-31 | CN¥731.44 Million ≈ $107.03 Million |
-- |
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, cardiovascular, urinary system (nephropathy), anesthesia and pain, and anti-androgen. The company was founded in 2001 and is based in Shengz… Read more